Gastroesophageal reflux disease symptomatic

Van Zyl, J., Van Rensburg, C., Vieweg, W., and Eischer, R. (2004) Efficacy and safety of pantoprazole vs ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. Digestion. 70, 61-69. 

Short-term treatment of symptomatic gastroesophageal reflux disease—15 mg once daily for up to 8 weeks Short-term treatment of erosive esophagitis—30 mg once daily for up to 8 to 16 weeks... 

Humphries TJ, Root JK, Hufnagel K (1991) Successful drug-specific chronotherapy with the H2 blocker famotidine in the symptomatic relief of gastroesophageal reflux disease. AnnNY Acad Sci 618 517... 

Gastroesophageal reflux disease (GERD)—Symptomatic cUnical condition or histologic alteration that results from episodes of gastroesophageal reflux. 

Cisapride, a serotonin4 receptor agonist (10 mg p.o. q.i.d.) with gastrointestinal prokinetic properties, is indicated in the symptomatic treatment of nocturnal heartburn due to gastroesophageal reflux disease. 

Observational studies In an open study of rabeprazole 20 mg/day for 8 weeks in 2579 patients with gastroesophageal reflux disease and endoscopically confirmed erosive esophagitis, there was substantial symptomatic relief [74 ]. The most common adverse events included abdominal pain (1.2%), chest pain (0.5%), diarrhea (1.5%), dizziness (0.7%), dyspepsia (0.6%), belching (0.5%), headache (1.6%), nausea (1.0%), rashes (0.5%), and upper respiratory tract infections (0.5%) 15% of patients reported at least one adverse event, 2.4% withdrew because of adverse events, and 1.4% reported a serious adverse event. All the serious adverse events were considered to... 

Placebo-controlled studies A double-blind, placebo-controlled, randomized study of maintenance intermittent treatment with rabeprazole 20 mg/day in patients with symptomatic gastroesophageal reflux disease without esophageal erosions included a first phase of run-in with single-blind placebo for 2 weeks, a second open phase of acute treatment with rabeprazole 20 mg/day ( = 388) for 4 weeks, and a third doubleblind, placebo-controlled, intermittent maintenance phase with rabeprazole 20 mg/day ( = 200) for 6 months [75 ]. Rabeprazole was more effective than placebo. During the acute treatment phase, 52 adverse events in 26 patients were judged to be possibly or probably related to rabeprazole, the most common being nausea, diarrhea, abdominal pain, and headache. During the intermittent maintenance phase, the most common adverse events compared with placebo included diarrhea (6.8% versus 1%), nausea (4.9% versus 3.1%), and headache (4.9% versus 3.1%). 

Children Infants and children (21 days to 3.3 years of age) with symptomatic gastroesophageal reflux have been treated with metoclopramide at a dosage of 0.5 mg/kg/day symptoms improved, the duration of the disease was shortened, and surgery was avoided. 

In current clinical practice, many patients with symptomatic gastroesophageal reflux are treated empirically with medications without prior endoscopy, ie, without knowledge of whether the patient has erosive or nonerosive reflux disease. Empiric treatment with proton pump inhibitors provides sustained symptomatic relief in 70-80% of patients, compared with 50-60% with H2 antagonists. Due to recent cost reductions, proton pump inhibitors are increasingly being used as first-line... 

---